Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for plaque progression in stable CAD
NCT06342609Phase 4Completed
- Sponsor
- The Lundquist Institute
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronary artery disease (CAD) comparing Colchicine with Placebo (2 arms). Primary endpoint: Rate of change in low attenuation plaque volume at 12 months. Started Mar 2023; status: completed.
02
Drugs
colchicine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06342609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342609.